Skip to Content

Lyrica Approval History

Lyrica (pregabalin) is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and spinal cord injury; as an adjunctive therapy for partial onset seizures and for the treatment of fibromyalgia.

Development History and FDA Approval Process for Lyrica

DateArticle
Oct 12, 2017Approval FDA Approves Lyrica CR (pregabalin) Extended-Release Tablets for Neuropathic Pain Conditions
Jun 21, 2012Approval FDA Approves Lyrica For The Management Of Neuropathic Pain Associated With Spinal Cord Injury Based On Priority Review
Jun 22, 2007Approval FDA Approves First Drug for Treating Fibromyalgia - Lyrica
Dec 31, 2004Approval Lyrica Pfizer Inc. - Treatment for Neuropathic Pain
Sep  2, 2004Pfizer Statement on Regulatory Status of Lyrica

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide